Home » Stocks » RDY

Dr. Reddy's Laboratories Ltd. (RDY)

Stock Price: $74.06 USD 1.45 (2.00%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 12.26B
Revenue (ttm) 2.32B
Net Income (ttm) 258.59M
Shares Out 165.77M
EPS (ttm) 1.58
PE Ratio 46.93
Forward PE 31.15
Dividend $25.00
Dividend Yield 33.76%
Trading Day June 11
Last Price $74.06
Previous Close $72.61
Change ($) 1.45
Change (%) 2.00%
Day's Open 73.00
Day's Range 72.88 - 74.11
Day's Volume 168,062
52-Week Range 51.12 - 74.11

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer. The post 7 Best Vaccine Stocks for Their Pipeline Potential appeared first on ...

Other stocks mentioned: OCGN, SNY, VALN, ARCT, CVAC, NVAX
1 week ago - InvestorPlace

DUBAI, UAE, June 3, 2021 /PRNewswire/ -- Healthcare solutions provider Global Response Aid (GRA) today reported seven-month global sales figures for its anti-viral tablet Avigan®/Reeqonus™, a drug being...

1 week ago - PRNewsWire

Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2021.

3 weeks ago - Zacks Investment Research

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy...

1 month ago - Business Wire

The large generics manufacturer's share price is up more than 35% over the past year.

1 month ago - The Motley Fool

Tired of expensive stocks being just of reach? Look abroad for some great buying opportunities.

Other stocks mentioned: GILD, TX
1 month ago - The Motley Fool

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy'...

1 month ago - Business Wire

3 Generic Drug Stocks to Watch Amid COVID-Related Recovery

Other stocks mentioned: AMPH, BHC, TEVA
1 month ago - Zacks Investment Research

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) today announced that it has received the permission from the Drug Controller Gen...

1 month ago - Business Wire

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy'...

2 months ago - Business Wire

New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such...

3 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). ...

3 months ago - Newsfile Corp

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy...

3 months ago - Business Wire

Dr. Reddy's Laboratories Ltd (NYSE: RDY) has initiated the process with the Drugs Controller General of India for Emergency Use Authorization (EUA) of the human adenoviral vector-based platform COVID-19...

3 months ago - Benzinga

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy's”) today announce...

3 months ago - Business Wire

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy'...

3 months ago - Business Wire

HYDERABAD, India and PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Redd...

3 months ago - Business Wire

With the trading day more than halfway over, the broad markets were pushing much higher on Tuesday.

Other stocks mentioned: ALL, CRUS, EA, Z, ZG, COLM, MCFE ...
4 months ago - 24/7 Wall Street

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy'...

4 months ago - Business Wire

Dr. Reddy's (RDY) earnings decline while sales grow year over year in third-quarter fiscal 2021.

4 months ago - Zacks Investment Research

Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q3 2021 Results - Earnings Call Transcript

4 months ago - Seeking Alpha

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and the ni...

4 months ago - Business Wire

Dr. Reddy's (RDY) and Global Response Aid FZCO terminate the Avigan study conducted in Kuwait, focused on moderate-to-severe COVID patients in a hospital setting.

4 months ago - Zacks Investment Research

KUWAIT CITY, Jan. 27, 2021 /PRNewswire/ -- Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") and...

4 months ago - PRNewsWire

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy's”) and Global Res...

4 months ago - Business Wire

Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.

4 months ago - Zacks Investment Research

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of I...

4 months ago - Business Wire

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that the independent Data and Safety Monitoring Board (DSMB) has reviewed the safe...

5 months ago - Business Wire

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy...

5 months ago - Business Wire

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) will announce results for the third quarter ended December 31, 2020 on Friday, J...

5 months ago - Business Wire

Here we discuss four emerging market stocks, BCAUY, BIDU, IMPUY and RDY, which have solid growth prospects for 2021.

Other stocks mentioned: BIDU, IMPUY, BCAUF, BCAUY
5 months ago - Zacks Investment Research

HYDERABAD, India & MISSISSAUGA, Ontario & HALIFAX, Nova Scotia--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as ...

5 months ago - Business Wire

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY referred to as “Dr. Reddy's”) today announced the secondary listing of its Americ...

6 months ago - Business Wire

3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty

Other stocks mentioned: BHC, TEVA
6 months ago - Zacks Investment Research

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), and Russian Direct Investment Fund (RDIF) announced today that they have commenced adaptive phase...

6 months ago - Business Wire

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announc...

7 months ago - Business Wire

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announc...

7 months ago - Business Wire

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today annou...

7 months ago - Business Wire

Dr. Reddy's (RDY) earnings decline year over year while sales increase in second-quarter fiscal 2021.

7 months ago - Zacks Investment Research

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Depart...

7 months ago - Business Wire

Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q2 2021 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that Parag Agarwal will be joining the Company as Chief Financial Officer (Designa...

7 months ago - Business Wire

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter and the half year ended Septe...

7 months ago - Business Wire

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announc...

7 months ago - Business Wire

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, today announced that th...

7 months ago - Business Wire

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the second quarter ended September 30, 2020 on Wednesday, October 28th, ...

8 months ago - Business Wire

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has joined the Science Based Targets initiative’s (SBTi) business ambition for 1.5°C, becoming the...

8 months ago - Business Wire

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announc...

8 months ago - Business Wire

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announc...

8 months ago - Business Wire

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr.Reddy’s”) today announce...

8 months ago - Business Wire

About RDY

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished ... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1984
CEO
G. Prasad
Country
India
Stock Exchange
NYSE
Ticker Symbol
RDY
Full Company Profile

Financial Performance

In 2019, RDY's revenue was 174.60 billion, an increase of 13.49% compared to the previous year's 153.85 billion. Earnings were 19.50 billion, an increase of 3.74%.

Financial numbers in millions INR.
Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for RDY stock is "Buy." The 12-month stock price forecast is 80.78, which is an increase of 9.07% from the latest price.

Price Target
$80.78
(9.07% upside)
Analyst Consensus: Buy